Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. malvern, pa., nov. 02, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. the market grew at a rate of 15.5% from 2015 to culminate in a market of $1.60b in 2021. . Ocugen Inc is expected to have a median price target of $7 per share during the 12-month period, according to four analysts who cover the company. About. Central Washington University hosted the annual Symposium for University Research and Creative Expression (SOURCE) conference virtually from May 16-21, starting with a welcome event. Ocugen reported a $0.13 net loss per share for the three months ended June 30, 2021 compared to a $0.19 net loss per share for the three months ended June 30, 2020. MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a . Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. By Sarah Smith, Editor, Today's Market Apr 12, 2021, 12:29 pm EST. Conference Call and Webcast Details Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its second quarter 2021 financial results and provide a business update at 8 . November 2, 2021 - 6:08 pm. MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8 . Travel/Hotel Details. However, globally, almost 1 billion children suffer MALVERN, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its third quarter 2021 financial results and . The 2 nd Annual Dry AMD Therapeutic Development conference requires registration for attendance. Chester County biopharmaceutical company Ocugen has finalized an agreement with Bharat Biotech of India to co-develop Bharat's Covid-19 vaccine for the United States market. ET on Friday, May 7, 2021. Conference Call and Webcast Details. Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. May 3, 2021 - 4:35 pm. S&P 500 0.00%. ET to discuss the fourth quarter and full year 2021 financial results and provide an update on business. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene . MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi's 16th Annual BioPharma Virtual Conference being held on . "Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET U.S. FDA lifts clinical hold on IND application for COVAXIN (BBV152), clearing the pathway for Phase 2/3 clinical trial in support of a BLA submission MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness . Implied volatility shows how much movement the market is expecting . MALVERN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference . Ocugen Provides Business Update and Third Quarter 2021 Financial Results November 9, 2021 PDF Version Conference Call and Webcast Today at 8:30 a.m. Dear Stockholder: We are pleased to invite you to attend Ocugen, Inc.'s 2021 Annual Meeting of Stockholders (the . DOW 0.00%. Ocugen (NASDAQ: OCGN) is . Ocugen Inc NASDAQ Updated Jun 2, 2022 11:59 PM. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update February 18, 2022 PDF Version July 30, 2021 - 8:45 am. 2021 Financial Results. Ocugen reported a $0.09 net loss per share for the three months ended March 31, 2022 compared to a $0.04 net loss per share for the three months ended March 31, 2021. Ocugen reported a $0.09 net loss per share for the three months ended March 31, 2022 compared to a $0.04 net loss per share for the three months ended March 31, 2021. 1-5 November 2021 CONFERENCE OUTCOME STATEMENT . Press question mark to learn the rest of the keyboard shortcuts We have completed three quarters of 2021 and our Ocugen family has grown significantly, committed to bringing Covaxine BBV152, our COVID-19 vaccine candidate to the United States and Canada. 2021 ANNUAL MEETING OF STOCKHOLDERSTo be Held on June 11, 2021. ET to Discuss First Quarter 2021 Financial Results and Provide May 3, 2021, 8:35 PM UTC Share this article Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473 (international) Conference ID: 9757658: Webcast: Available in the "Investors" section of the Ocugen website by clicking here and archived . MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a . ocugen host conference call friday february 25 830 am et discuss Press Release Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. The 2021 Premier Volleyball League Open Conference was the tenth conference of the Premier Volleyball League (37th conference of the former Shakey's V-League) and its first conference as a professional league. Ocugen's cash, cash equivalents, and restricted cash totaled $107.5 million as of September 30, 2021, compared to $24.2 million as of December 31, 2020. Over the course of the week, each of the CWU colleges and programs had a day in the spotlight, starting with the College of the . MALVERN, PA Ocugen, Inc. (NASDAQ: OCGN) announced that it will host a conference call to discuss its third quarter 2021 financial results and provide a business update at 8:30 a.m. 9:00 A.M. (ET) - 3:00 P.M. (ET) - One-On-One Investor Meetings. . MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business . Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at . In a virtual address to the "AI and Cyber - An Abundance of Potential" conference on Monday (27 September 2021), Deputy Secretary General Mircea Geoan stressed that NATO is determined to set the standard for the ethical use of emerging and disruptive technologies. The increase was primarily driven by. quickly & with much less cost. MALVERN, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to fight COVID-19, today announced that it will present at the 2021 CTIC 5 th Healthcare Investment Summit being held on January 9-10, the H.C. Wainwright BioConnect . April 28, 2021. Dr. Upadhyay will be speaking on October 20, 2021, at 3:15pm Eastern Time. General and administrative expenses for the quarter ended March 31, 2021 or $4.2 million, compared to $2.3 million for the three-month ended March 31, 2020. May 17, 2021 By Larry Ramer, InvestorPlace Contributor May 17, 2021, 10:37 am EDT May 17, 2021 After reviewing the . Trending now. Interestingly, Sanofi will be one . Thursday, May 26, 2022. malvern, pa., march 08, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. We have completed three quarters of 2021 and our Ocugen family has grown significantly, committed to bringing Covaxine BBV152, our COVID-19 vaccine candidate to the United States and Canada. malvern, pa., nov. 02, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Rooms Shows Rankings Earnings Newsletters Shop. Ocugen had 198.9 million shares of common stock outstanding as of September 30, 2021. NASDAQ 0.00%. OCGN Intrinsic Value: Projected FCF as of today (June 06, 2022) is $-0.70. . OCU410 is the second drug candidate from Ocugen's Modifier Gene Therapy Platform, which is expected to enter clinical trials in 2022. That is because the Jun 17, 2022 $0.50 Call had some of the highest implied volatility of all equity options today. On August 6, 2021, Ocugen, Inc. ("the Company") issued a press release announcing its financial results for the quarter ended June 30, 2021. for the year ended december 31, 2021, ocugen reported a net loss of approximately $58.4 million, or $0.30 net loss per share, compared to net loss of approximately $34.4 million, or $0.31 net loss. Cancel. The Company has scheduled a conference call and webcast for 8:30 a.m. eastern time on August 6, 2021 to discuss these financial results and business updates. Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results February 25, 2022 PDF Version Conference Call and Webcast Today at 8:30 a.m. The conference started on July 17, 2021 and ended on August 13, 2021, at the PCV Socio-Civic and Cultural Center in Bacarra, Ilocos Norte in a bubble. ET on Friday, February 25 . MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness . Ocugen Provides Business Update and First Quarter 2021 Financial Results May 7, 2021 PDF Version Conference Call and Webcast Today at 8:30 a.m. Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference. [1] [2] [3] The conference started on July 17, 2021 and ended on August 13, 2021, at the PCV Socio-Civic and Cultural Center in Bacarra . MALVERN, PA Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8:30 a.m. Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness . Ocugen's senior management team will host the . March 12, 2021 - 5:45 pm. Investors are invited to participate on the call using the following details: Ocugene. September 7, 2021 - 5:22 pm. Press J to jump to the feed. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update https://t.co/sBLgNkrfSL" malvern, pa., feb. 18, 2022 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. The 2021 Premier Volleyball League Open Conference was the tenth conference of the Premier Volleyball League ( 37th conference of the former Shakey's V-League) and its first conference as a professional league. H. C. Wainwright has a block of rooms at the Fontainebleau Hotel. Ocugen's senior management team . Ocugen, develops novel solutions to medical challenges, to deliver new breakthroughs for people living with disease. Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business updates. MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi's 16th Annual BioPharma Virtual Conference being held on September 8-10, 2021 and at the H.C . ET Emergency Use Authorization application filed with the U.S. FDA for the COVID-19 vaccine candidate, COVAXIN (BBV152), for children aged 2 - 18 years You may book discounted hotel rooms at the Fontainebleau Hotel via . MALVERN, Pa. November 9, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, . lives of COVID-19, announced today that it will host a conference call to discuss its fourth quarter and full . Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business updates. malvern, pa., july 30, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from covid-19, today announced that it will host a conference call to discuss its second quarter 2021 Third Quarter 2021 Financial Results. Conference Call and Webcast Details.